Secondary Logo

Institutional members access full text with Ovid®

Malignancies in Inflammatory Bowel Disease

Frequency, Incidence and Risk Factors—Results from the Swiss IBD Cohort Study

Scharl, Sylvie, MD1; Barthel, Christiane, MD1; Rossel, Jean-Benoit, PhD2; Biedermann, Luc, MD1; Misselwitz, Benjamin, MD1; Schoepfer, Alain M., MD3; Straumann, Alex, MD1; Vavricka, Stephan R., MD1; Rogler, Gerhard, MD, PhD1; Scharl, Michael, MD1; Greuter, Thomas, MD1

American Journal of Gastroenterology: January 2019 - Volume 114 - Issue 1 - p 116–126
doi: 10.1038/s41395-018-0360-9
ARTICLES
Buy
SDC

BACKGROUND: Malignancy may occur as long-term complication of inflammatory bowel disease (IBD) due to different risk factors. We assessed prevalence and incidence of malignancy, and predictive factors in the Swiss IBD Cohort Study (SIBDCS).

METHODS: All IBD patients in the SIBDCS were analyzed from a cross-sectional and longitudinal perspective. Patients with malignancies were compared to controls. Standardized incidence ratios (SIR) were calculated based on age-specific and sex-specific background rates.

RESULTS: Malignancies were identified in 122 of 3119 patients (3.9%). In a logistic regression model, age (OR 1.04 per year), intestinal surgery (OR 3.34), and treatment with steroids (OR 2.10) were the main predictors for the presence of malignancy, while treatment with 5-ASA (OR 0.57) and biologics (OR 0.38) were protective. From a longitudinal perspective, 67 out of 2580 patients (2.6%) were newly diagnosed with malignancy during a follow-up of 12,420.8 years (median 4.9 years). While there was no increased risk for malignancy overall (SIR 0.93, 95% CI 0.72–1.18) and colorectal cancer (SIR 1.55, 95% CI 0.71–2.95), IBD patients had an increased risk for lymphoma (SIR 2.98, 95% CI 1.36–5.66) and biliary cancer (SIR 6.3, 95% CI 1.27–18.41). In a Cox regression model, age and recent use of immunomodulators were the main predictors for development of malignancies, while 5-ASA, biologics were protective.

CONCLUSIONS: IBD patients showed increased risk for lymphoma and biliary cancer, but not colorectal cancer and cancer overall. Age and recent use of immunomodulators were the main risk factors for malignancy, while aminosalicylates and biologics appear to be protective.

1Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland;

2Institute of Social and Preventive Medicine, University Hospital Lausanne—CHUV, Lausanne, Switzerland;

3Division of Gastroenterology and Hepatology, University Hospital Lausanne—CHUV, Lausanne, Switzerland.

Correspondence: Thomas Greuter, MD. E-mail: thomas.greuter@usz.ch.

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/A30 and http://links.lww.com/AJG/A31

These authors contributed equally: Michael Scharl and Thomas Greuter. Members of the Swiss IBD Cohort Study Group are listed below the Acknowledgements.

Received February 20, 2018

Accepted September 09, 2018

© The American College of Gastroenterology 2019. All Rights Reserved.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website